Drug Profile
Cancer vaccine NY-ESO-1 - CSL/Ludwig Institute for Cancer Research
Alternative Names: ESO-1 IMX®; ISCOMATRIX® ESO1 Therapy; Melanoma vaccine NY-ESO-1 - CSL; NY-ESO-1 ISCOMATRIX® vaccine; NY-ESO1 protein/ISCOM® adjuvantLatest Information Update: 10 Oct 2021
Price :
$50
*
At a glance
- Originator CSL; Ludwig Institute for Cancer Research
- Developer Ludwig Institute for Cancer Research
- Class Cancer vaccines; Peptide vaccines; Peptides; Saponins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 03 Sep 2015 No recent reports on development identified - Phase-II for Malignant melanoma (Inoperable/Unresectable, Metastatic disease) in Australia (IM)
- 03 Sep 2015 No recent reports on development identified - Phase-II for Malignant melanoma in New Zealand, United Kingdom (IM)
- 20 Apr 2010 This vaccine is still in phase II trials for Malignant melanoma